Reconstitution Solution

Recent research & studies

• Can physician-supervised medical students expand access to infant basic life support training? A prospective quasi-experimental study on long-term knowledge retention among caregivers. — PubMed • Franco Bueno CD et al. • Resusc Plus • 2026 Sep

  Unlabelled: Infants are particularly vulnerable to cardiorespiratory arrest and choking, emergencies that often occur at home and require immediate intervention. Training parents and caregivers in Basic Life Support (BLS) can improve early emergency response, but access to qualified instructors remains…

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) — ClinicalTrials.gov • Recruiting • Phase3 • August 24, 2026

  The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18…

• Human Experimental Models of Pain (HEMP) — ClinicalTrials.gov • Not Yet Recruiting • Na • August 24, 2026

  This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The…

• Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS — ClinicalTrials.gov • Available • August 24, 2026

  The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS). No formal clinical hypotheses are being evaluated with concurrent controls. Secondary objectives include…

• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — ClinicalTrials.gov • Recruiting • Phase3 • August 24, 2026

  Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical…

• Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. — ClinicalTrials.gov • Active Not Recruiting • Phase2 • August 24, 2026

  This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or…

These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.